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EXECUTIVE SUMMARY

Hayes, Susan. Hepatitis C Screening. Unpublished Doctor of Nursing Practice capstone
project, University of Northern Colorado, 2016.
Hepatitis C virus (HCV) is the most common blood-borne pathogen in the United
States. The “Baby Boomer” population, adults born between the years 1945 and 1965, is
considered a high-risk population as 75% of adults with HCV were born within this
timeframe. The U. S. Preventive Services Task Force (USPSTF) made it a Grade B
recommendation in 2013 for all adults born in this birth cohort to be screened for HCV
even if asymptomatic. Hepatitis C virus is associated with many negative sequela
including liver fibrosis, cirrhosis, hepatocellular carcinoma, and death. With successful
treatment regimens available that yield a 90-100% cure rate, it is prudent and
recommended to screen this birth cohort.
Eagle Ridge Medical located in Brighton, Colorado and its sister clinic located in
Fort Lupton, Colorado do not currently have a standardized approach for HCV screening
of this population. The researcher of this project has therefore implemented an approach
for screening that includes an electronic health record (EHR) initiation of a screening
alert (reminder) for the four physicians at these clinics. She also mailed an informative
letter to this population that included information about the national recommendation and
screening of this birth cohort in an attempt to increase screening rates at these
organizations. This birth cohort includes adults born between the years 1945 and 1965.
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The researcher performed a chart audit of 5% of this population that included 1,906
patients in this birth cohort (N = 95) both before and after implementation of this project
to compare screening rates. The researcher also performed a chart audit on patients who
were seen in both of these clinics six weeks prior and six weeks after project
implementation; 466 patients were seen in the six weeks prior to implementation and
three of them had been screened for HCV (0.6%) and 421 patients were seen in the six
weeks after the project implementation and 57 of them had been screened for HCV
(13.5%). The researcher anticipated screening rates would increase after this project had
been implemented--they did as they rose by 4.1% using the 5% systematic sampling
method and 12.9% during the six-week study period in which one positive result was
noted. Many of the individuals born within this population have many years left to live if
successfully treated and ultimately deserve the opportunity to be screened for HCV and
treated accordingly. The effects of this study are expected to have a positive impact for
the future of this birth cohort. Identifying patients who are positive for HCV will allow
them the opportunity for treatment and a high potential of HCV eradication as there is a
90-100% cure rate.
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CHAPTER I

PROBLEM STATEMENT

Introduction
Hepatitis C virus (HCV) is a blood-borne disease and a global problem that
impacts multiple individuals. Hepatitis C virus was first recognized in 1974 but it was
not until 1989 that it was classified by molecular means. Hepatitis C virus is a “positivestrand RNA virus that belongs to the family Flaviviridae” (Kesli, Polat, Terzi, Kurtoglu,
& Uyar, 2011, p. 4089). Hepatitis C is either acute--with an incubation phase of about 6
to 10 weeks--or chronic in nature. In the acute phase, the individual is generally
asymptomatic and rarely encounters grave diseases. Approximately 15-25% of infected
individuals naturally clear Hepatitis C virus within six months of exposure without any
medical management or intervention. Reasons for this spontaneous clearance of the virus
are not known. The remaining 75-85% of individuals will go on to develop chronic
Hepatitis C infection (Centers for Disease Control and Prevention [CDC], 2016).
Chronic Hepatitis C is diagnosed when a patient is positive for the virus for longer than
six months. Chronic hepatitis C causes multiple serious sequela, some can be fatal: liver
fibrosis or cirrhosis, liver failure, and hepatocellular carcinoma. Hepatitis C virus is the
“leading cause of death from liver disease and the most common reason for liver
transplantation in the United States” (Fathauer & Meek, 2012, p. 338).
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Multiple factors are involved with the risk of contracting HCV. Individuals who
partake in high-risk activities such as injection drug use (either current or former and
those who injected only one time if it was done many years ago) are at high risk of
contracting HCV. Other individuals at risk include recipients of clotting factor
concentrates made before 1987 when more progressive safe approaches of manufacturing
of these concentrates were established. Recipients of solid organ transplants or blood
transfusions before 1992, when universal screening measures were introduced, are also
considered at high-risk. Individuals who undergo or underwent chronic hemodialysis or
those with identified contact with HCV such as healthcare workers receiving a needle
stick injury of someone who is positive for HCV or recipients of organs or blood from a
donor who tested positive for HCV are also at high-risk. Other high-risk individuals
include those who are human immunodeficiency virus (HIV)-positive and children born
to mothers who are HCV-positive.
Another high-risk population is the “Baby Boomer” generation or persons born
between the years 1945 and 1965. It is estimated that 75% of adults with Hepatitis C
virus were born between 1945 and 1965. With this alarming percentage, it is not
surprising a current recommendation by the U. S. Preventive Services Task Force
(USPSTF; 2013) was for these individuals to be screened once in their lifetime even if
they are asymptomatic. The USPSTF deemed this a high-risk population and a
recommendation was issued in 2013, making it a Grade B recommendation to be
screened. Previously, the USPSTF recommended against screening (Grade D
recommendation) for adults not deemed being at a heightened risk of infection;
insufficient evidence was found with regard to screening adults at high risk of infection
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(Grade I recommendation). Appendix A provides Grade Definitions and Levels of
Certainty Regarding Net Benefit from the USPSTF. There are various reasons why this
particular population is at high risk: blood or blood product transfusions (as these
products not screened for blood-borne diseases since universal screening was not
implemented until 1992), intravenous drug use, and receiving unregulated tattoos. The
Hepatitis C virus is transmitted through blood products (transfusions), needle stick
injuries or sharing needles for various reasons including drug use, and in health care
settings due to reusing items or improper sterilization of equipment consisting mostly of
needles or syringes. The Hepatitis C virus can also be transmitted through sexual contact
and childbirth; however, the virus is less commonly transmitted by these particular
modes.
The Surgeon General, Boris Lushniak MD, provided his perspectives on testing
the “Baby Boomer” population for HCV. Dr. Lushniak (2014) pointed out that over the
last 15 years, limiting testing to those individuals with specific risk factors and medical
symptoms has yielded limited success:
HCV is also the most common reason for liver transplantation and a leading cause
of liver cancer, the fastest-rising cause of cancer-related death in the U.S.
treatment for HCV is curative, however, and has been shown to reduce all-cause
mortality among cured individuals. (p. 220)
The USPSTF (2015) and the CDC (2016) recommend providing a one-time screening to
adults born amongst this birth cohort for HCV. With serious health complications that
result from the Hepatitis C virus and a low level of diagnosis and management, it is
prudent for this high-risk population, the Baby Boomers, to be tested one time in their
lives. This “recommendation enables medical providers to offer HCV testing to baby
boomers routinely, without the barrier of discussing stigmatized risk behaviors”
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(Lushniak, 2014, p. 220). The Surgeon General urges this population be screened and
tested for HCV to prevent diseases of the liver and possible death.
According to the CDC (2016), individuals in the early stages of HCV infection
are typically asymptomatic but when symptoms of HCV do occur, they include fatigue,
urine dark in color, fever, pale clay-colored stool, decreased appetite, abdominal pain,
arthralgia, jaundice of the skin, nausea, and vomiting. If a person presents with these
particular signs and symptoms, it may be advantageous to test the individual for HCV.
Having an increased alanine aminotransferase (ALT), a component of the liver function
test, may also be indicative of the Hepatitis C virus, or at least another type of underlying
disease of the liver, and should be checked if suspicious for HCV infection.
Testing for the Hepatitis C virus is relatively simple. Initially, a serum blood
draw testing for anti-HCV antibody is performed. If positive or equivocal, a serum HCVRNA (ribonucleic acid) blood draw is performed as a positive anti-HCV antibody does
not necessarily confirm the diagnosis. A positive anti-HCV only means the individual
has been exposed to the Hepatitis C virus either currently or in the past. The CDC (2013)
recommends “an FDA-approved NAT [Nucleic Acid Testing] assay intended for
detection of HCV RNA in serum or plasma from blood of at-risk patients who test
reactive for HCV antibody should be used” (Testing for HCV RNA section, para. 1). If
the HCV-RNA is positive, the patient is diagnosed with active chronic Hepatitis C and
may potentially receive treatment. The sensitivity and specificity of the anti-HCV
antibody test are 97% and 100%, respectively. A sensitivity result of
97% indicates that the screening test will detect at least 97% of individuals who
have been exposed. A specificity of 100% indicates that 100% of individuals
without Hepatitis C had a negative screening test with no false-positive test
results. (Joshi, 2014, p. 665)
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The sensitivity of the serum HCV-RNA test varies based on which test is
performed. An exact percentage could not be located; however, it is stated that “PCR
[polymerase chain reaction] tests detect HCV RNA in the blood, which indicates current
active infection. This type of quantitative PCR test is very sensitive and can measure as
few as 5-10 IU/mL” (Franciscus & Highleyman, 2014, p. 1). The specificity of the HCVRNA tests is 99.98% (Tillmann, 2014, p. 6702). With high sensitivity and specificity
levels of the tests, it is prudent to screen individuals who are deemed at high risk in order
to treat them and also decrease exposure to others who do not have HCV.
Research Question
Q1

In adults born between the years 1945-1965 (P--Population), does a
systematic population approach to Hepatitis C screening (I--Intervention)
versus the provider assessing for high risk factors in the context of routine
health and illness care (C--Comparison) result in increased screening (O-Outcome)?
Background and Significance of Project

The purpose of this capstone project was to implement Hepatitis C virus screening
at the Eagle Ridge Medical and Fort Lupton clinics for patients born between the years
1945 and 1965--the population also known as the Baby Boomer generation (see
Appendix B for Statement of Mutual Agreement). This generation has been deemed by
the USPSTF (2015) as a high-risk population; therefore, it is not only prudent but also
recommended to screen men and women of this population at least once in their lifetime.
With successful treatment options available that currently yield a 90-100% cure rate, it is
important to screen this population so they can begin a treatment regimen if warranted
and not contraindicated.
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Hepatitis C virus is associated with multiple negative sequela and treatment is
therefore prudent and advised. Chronic “hepatitis C may eventually progress to cirrhosis,
liver decompensation and hepatocellular carcinoma and many studies proved that HCV
eradications reduce the risk of developing liver complications” (Calvaruso & Craxi,
2016, p. 7). Treatment methods currently exist for active chronic HCV, barring the
patient does not have underlying liver disease. Furthermore, treatment therapies vary
based on the six known HCV genotypes and subsequent subtypes. A gastroenterologist
or hepatologist are specialty physicians who would initiate treatment therapy and monitor
the effects of it. Most commonly, HCV infection is affiliated with Genotype 1.
Treatment-naïve patients who express Genotype 1 are initially treated with direct-acting
antivirals (DAAs) and sometimes with or without ribavirin, depending upon the
medication combination. This treatment regimen is interferon-free (Chopra & Muir,
2015, Treatment-naïve Patients section, para. 1). It has been found that
HCV exhibits an extraordinarily high degree of genetic diversity--substantially
greater than that of the HIV-1 pandemic--creating a major challenge for the
development of both HCV vaccines and pan-genotypic drug therapies. (Messina
et al., 2015, p. 78)
For this reason alone, one can see why it is important for genotype testing to be
completed so the treatment may target the genotype and ensure a higher success rate of
treatment. Messina et al. (2015) stated:
At present, the duration of treatment, cure rates, and the need for adjuvant
interferon and ribavirin with the new DAA therapies remain dependent in part on
HCV genotype and subtype. Therefore, the development of national treatment
strategies using DAA therapies requires a detailed understanding of the relative
HCV genotype prevalence and subtypes. (p. 78)
Direct-acting antiviral therapies generally produce more tolerable side effects than do
peginterferon-alfa and ribavirin. Particularly, second generation DAA therapies such as

7
the protease inhibitor simeprevir are generally well tolerated and have minimal side
effects such as
photosensitivity and rash [that] were reported in the simeprevir program with
some serious reactions causing hospitalization. Patients should be cautioned
about this risk and instructed to use sun protective measures and limit sun
exposure. (Pockros, 2015, Second-generation Protease Inhibitors section, para. 5)
If the rash remains persistent or is severe in nature, it is recommended that the drug be
discontinued. Transient elevations in the bilirubin level have also been noted but no
reports of liver toxicity have been identified. Nausea and pruritus have also been
documented as side effects of simeprevir.
In addition to medication administration, Nguyen and Hu (2014) found,
All patients with chronic HCV need education and counseling on measures which
may be helpful in reducing progression of liver fibrosis. There are several studies
that have reported associations between excessive alcohol use and the progression
of liver fibrosis, development of HCC [hepatocellular carcinoma], and poorer
response to treatment. (p. 27)
If a patient is deemed to be an alcoholic, prior treatment of the alcoholism is prudent
before initiating pharmacological therapy.
In addition, if a patient does have underlying liver disease, treatment options are
still available; however, they are tailored to meet the needs of the patient in an attempt to
decrease the risk of causing further damage to the liver. Such treatment options include
interferon-free, direct-acting antiviral medications for patients with compensated liver
cirrhosis. While “interferon-free regimens appear effective and safe for such patients,
treatment should generally be undertaken in consultation with an expert in managing
patients with cirrhosis” (Chopra & Muir, 2015, Patients with Cirrhosis section, para. 1).
Medication options are
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limited for patients with decompensated liver cirrhosis (ascites, hepatic
encephalopathy, or gastroesophageal variceal hemorrhage), and antiviral
treatment should only be undertaken by or in close consultation with an expert in
the management of such patients, preferably at a transplant center. (Chopra &
Muir, 2015, Patients with Cirrhosis section, para. 4)
This population of patients also requires frequent laboratory and clinical monitoring and
observation.
According to Joshi (2014), the “universal screening recommendation is based on
the finding in the National Health and Nutrition Examination Survey [NHANES] that
approximately 75% of persons with a positive screening test and chronic HCV infection
were born during the years 1945-1965” (p. 665). The NHANES is a chief program of the
National Center for Health Statistics (NCHS) and is a part of the CDC (2014) with the
responsibility of generating fundamental and health statistics for the nation (Introduction
section, para. 1). With current available treatment, screening the Baby Boomer
generation for the Hepatitis C virus infection is recommended and pertinent. Many
individuals born within this timeframe have many years left to live if successfully treated;
thus, they deserve the opportunity to be screened for HCV and treated accordingly.
National and Regional Statistics
Globally, the Hepatitis C virus infection is significant. In 2005, it was estimated
that “more than 185 million people had Hepatitis C virus (HCV) antibodies (prevalence
of 2.8 percent)” (Chopra, 2015, Epidemiology section, para. 1). Areas with high to low
prevalence of HCV were identified. Areas with high prevalence (>3.5%) included the
Middle East, central and east Asia, and North Africa. Areas with moderate prevalence
(1.5 to 3.5%) included sub-Saharan Africa; south and southeast Asia; Andean, Central,
and southern Latin America; Oceania; the Caribbean; western, central, and eastern
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Europe; and Australasia including Australia, New Guinea, New Zealand, and nearby
Pacific islands. Areas with low prevalence (<1.5%) included tropical Latin America, the
Asian Pacific, and North America (Chopra, 2015).
In the United States, it is estimated that HCV is the most common blood-borne
disease. With approximately 17,000 new cases of HCV infection annually in the United
States, it is clear the incidence is decreasing as there were approximately 230,000 cases
per year in the 1980s. The “overall incidence in 2010 was estimated to be 0.3 per
100,000. The decline relates primarily to reduced infections in injection drug users, a
probable consequence of changes in injection practices motivated by a concern for HIV
risk” (Chopra, 2015, United States section, para. 1). After 1985, there were almost zero
cases of HCV infection due to transfusions. Deduced from analyses from the NHANES
between the years 2003 and 2010 with regard to the United States, the predictable
occurrence of
antibodies to HCV was 1.3 percent (reflecting an approximate 3.6 million people
with past or current HCV infection), and the estimated prevalence of HCV RNA
positivity was 1.0 percent (reflecting an approximate 2.7 million people with
chronic HCV infection). (Chopra, 2015, United States section, para. 4)
The highest prevalence was noted in individuals born between 1945 and 1965.
With this information alone, it is prudent to identify or accept this as a current,
global health problem and one that needs to be addressed. The Baby Boomer generation
has a high prevalence of Hepatitis C, “sixfold the prevalence among all other adults”
(Chopra, 2015, United States section, para. 7). Screening for Hepatitis C virus infection
is therefore a current recommendation from the USPSTF (2015) and should be
implemented in clinical practice. It is also worth noting that the researcher performed an
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extensive search of the literature; however, national screening rates for HCV could not be
obtained as available data did not exist.
Financial Impact
The economic burden from Hepatitis C virus infection and its affiliated sequela is
discussed from a national perspective of the United States. As of 2012, the “total cost is
estimated at $6.5 ($4.3-$8.4) billion and it will peak in 2024 at $9.1 ($6.4-$13.3) billion.
The lifetime cost of an individual infected with HCV in 2011 was estimated at $64,490”
(Razavi et al., 2013, p. 2164). Yet, this cost is considerably higher amongst people who
have a longer life expectancy. Appendix C provides a graph showing the total prevalence
and healthcare costs with 95% Confidence Intervals. Razavi et al. (2013) stated:
The majority of peak cost will be attributable to more advanced liver diseases –
decompensated cirrhosis (46%), compensated cirrhosis (20%), and HCC (16%).
The maximum cost associated with mild to moderate fibrosis (F0-F3) occurred in
2007 at nearly $780 million. The cost associated with compensated cirrhosis is
expected to peak in 2022 at $1.9 billion, while the peak cost for decompensated
cirrhosis and HCC is predicted to occur in 2025, with annual costs in excess of
$4.2 billion and $1.4 billion, respectively. (p. 2167)
It should be noted that “F0-F3” correlates with stages of fibrosis. Curry and Afdhal
(2015) identified five stages:


F0: No fibrosis



F1: Portal fibrosis without septa



F2: Few septa



F3: Numerous septa without cirrhosis



F4: Cirrhosis (Stages of Fibrosis section, para. 1).

Compensated liver disease is identified as the first two stages of liver disease
wherein the individual lacks varices or ascites in Stage 1 and is positive for varices and
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negative for ascites in Stage 2. Decompensated liver disease is identified as the third and
fourth stages of liver disease wherein the individual might be positive or negative for
varices and positive for ascites in Stage 3 and positive or negative for bleeding and
positive for ascites in Stage 4 (Thornton, 2015, Approach to the Evaluation of Patients
with Cirrhosis section, Figure 2).
As aforementioned, the lifetime cost of an HCV-positive person is approximately
$64,490. The lifetime cost of treating chronic hepatitis C sequela is boosted to $205,760
($154,890-$486,890) when medical cost inflation is taken into consideration (Razavi et
al., 2013, p. 2167). Ultimately, it is clear to see that the Hepatitis C virus is burdensome
and has a major financial impact in the United States.
Theoretical Framework
The reach, efficacy, adoption, implementation, and maintenance (RE-AIM)
framework adopted by Virginia Tech (2016) was utilized for the purpose of this capstone
project. The definitions of each component are discussed. Reach refers to the number of
individuals participating in the initiative and represents the number of people the
intervention will affect. Efficacy or effectiveness refers to the impact of the intervention
on outcomes. Adoption refers to the number of individuals willing to partake in the
intervention. Implementation refers to the “intervention agents’ fidelity to the various
elements of an intervention’s protocol. This includes consistency of delivery as intended
and the time and cost of the intervention” (Virginia Tech, 2016, Implementation section,
para. 1). Maintenance refers to the extent of the initiative becoming routine in the
practice. The goal of this framework was to encourage various individuals including
evaluators and policy-makers to be aware of the importance of and pay attention to
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“essential program elements including external validity that can improve the sustainable
adoption and implementation of effective, generalizable, evidence-based interventions”
(Virginia Tech, 2016, What is RE-AIM section, para. 1). The framework was originally
devised in 1999 and is applied frequently to research and translation of evidence to
practice. In their article, Glasgow, Vogt, and Boles (1999) acknowledged a need for
research methods that are devised to appraise the significance of interventions:
Abrams and colleagues defined the impact of an intervention as the product of a
program’s reach, or the percentage of a population receiving the intervention, and
its efficacy (I = R X E). We expand on this ‘RE’ (Reach X Efficacy) concept by
adding 3 dimensions that apply to the settings in which research is conducted
(Adoption, Implementation, and Maintenance: ‘AIM’) to more completely
characterize the public health impact of an intervention. (p. 1323)
This framework is also appropriate for evaluation of other areas related to health impact
including a specific population. However, there was no available research regarding
application of the RE-AIM framework to HCV screening and limited available research
with regard to other various diseases or disease screenings in general that were similar to
this particular project.
The study conducted by Liu and Perkins (2015) was pertinent to the aim of
increasing Hepatitis C virus screening rates as their study utilized the RE-AIM
framework for evaluating an intervention to improve screening rates for another clinical
screening recommendation. Just as HCV is the leading cause of death from liver disease
and the most common reason an individual would need a liver transplantation in the
United States, colorectal cancer is also a leading cause of death. The authors of this
particular study included patients aged 50-74 years, which is also a USPSTF (2016)
recommendation for colorectal cancer screening. The lay cancer screening navigator
contacted this birth cohort by phone and by letters in the mail if contact via phone was
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not achieved. Ultimately, the RE-AIM framework was utilized to evaluate the
intervention and increased screening rates were identified after utilizing the lay cancer
screening navigator. The results of this particular study in relation to the RE-AIM
framework are discussed.
Reach: 91.9% of qualified patients were contacted by the lay cancer screening
navigator; Effectiveness: At baseline, 28.6% of patients were already up to date
on their colorectal cancer screenings and after six months, 40.5% were current
and at 12 months, 42.2% were current; Adoption: All patients that were contacted
stated they were receptive to the intervention; Implementation: Out of the 368
mailed fecal test kits, 41% were returned (n=151) and 17.2% were positive
(n=26); Maintenance: There was not a significant difference amongst patients
who were current at the six and 12 month marks. (Liu & Perkins, 2015, p. 280)
The RE-AIM model was expected to guide this project to achieve similar results with
increased hepatitis C screening with a provider system reminder and counseling as
opposed to not screening or counseling the patient at all.
In a systematic review, Compernolle et al. (2014) utilized the RE-AIM framework
to explain the prospective public health impact of evidence-based multi-level
interventions to enhance obesity-related behaviors in adults. This review encompassed
35 multi-level intervention studies with the following inclusion criteria:
(1) the study included at least one outcome measure assessing obesity-related
behaviours (i.e. dietary, physical activity and sedentary behavior); (2) the study
collected data over at least one year; and (3) the study intervention was
community-based, multi-level, and targeted adults. (Compernolle et al., 2014, p.
149)
Overall, 32 intervention studies failed to report on all five components of the RE-AIM
framework and one-third of the intervention studies reported on the degree of
effectiveness. While most studies underreported their results within the RE-AIM
framework, the framework itself was still positively evaluated.
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The results of this systematic review are discussed.


Reach--58% of the population was aware of the intervention.



Effectiveness--89% of studies documented encouraging obesity-related
behavioral (71%) or overweight and obesity-related physiological results
(34%). Some of the studies reported on behavioral outcomes including
physical activity or inactive behavior and other studies reported on dietary
behaviors.



Adoption--adoption of interventions was stated in all 35 studies.



Implementation--entirety of implementation was stated in 29% of the studies
(n = 10) and in one study, implementation percentages varied from 17% for
widespread personal contacts with residents to 91% for the lending and
selling of pedometers.



Maintenance--at the individual level, eight interventions stated their health
behavior at a minimum of six months after the study period. At the level of
the organization, 16 interventions were continued until October of 2013.

This type of utilization of the RE-AIM framework is certainly not identical to
HCV screening; however, it is significant to discuss such studies that utilize this
framework to prove it does have benefit and is important in reflecting how research and
evidence are translated into practice.
With regard to this capstone project, to reach the intended population (adults born
between 1945 and 1965, which represents 1,906 patients), an alert in Micro Development
Services Incorporated (MDS), a system utilized within the electronic health record (EHR)
at Eagle Ridge Medical and Fort Lupton clinics, was created to alert the four physicians
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and act as a cue to action that the patient should be informed about Hepatitis C virus
screening recommendation if born between the years 1945 and 1965. The alert was a
screening reminder and was generated as a task in the EHR for providers when they
opened the patient’s chart. Informative letters intended to notify the patient of the
USPSTF’s (2015) recommendation to be screened for a blood-borne disease were mailed
to individuals born within this specific timeframe to give them an opportunity to be
screened in case they did not have an appointment with their provider over the next
several weeks.
Effectiveness was evaluated based on how many individuals born between the
years 1945 and 1965 were screened for the Hepatitis C virus after the screening trigger
interventions were implemented at the clinic. A chart audit was performed to establish
the current screening rate of this Baby Boomer population prior to the implementation
date of the screening trigger alert for the Hepatitis C virus and sending the informative
postal letters to this population; the chart audits took place on 5% of the patients (n = 95).
Adoption of the intervention for this capstone project was achieved. Four
physicians and staff members of the clinic, including the office manager, deemed this
project as feasible and also valuable to the clinic. A meeting was held with regard to this
capstone project and discussion ensued. The providers agreed this project was important
and also agreed the clinic had not been implementing any type of standard for screening
the Baby Boomer generation. The providers and staff were in agreement that the
researcher could move forward with the project.
Implementation of the intervention was achieved in April of 2016 following
Institutional Review Board (IRB) approval (see Appendix D). With encouragement and
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support from the providers, the student anticipated adherence from the providers to
ensure the patients were being screened. Dissemination of the message occurred in
person as to when the providers should start screening the patients; the providers had
already been educated on what the alert would look like within the EHR system. The
alert cannot be turned off by the provider and appears every time the patient’s chart is
opened. Willingness to change provider practice and implement HCV screening was
gained prior to implementation through a meeting held with the physicians. Provider
compliance with the screening alert was assessed after the first week of implementation.
Simply, the researcher discussed with each of the providers seven calendar days after the
screening alert for HCV was created in the EHR system to gather information as to
whether or not they were addressing the screening alert and subsequently screening the
Baby Boomer population. All four physicians (100%) stated they had been screening this
patient population and that it was helpful the EHR alert was implemented as a reminder.
The researcher addressed 1,906 envelopes and worked closely with the office manager to
ensure the postal letters were sent to patients born between the years 1945 and 1965. Per
the office manager, the office assumed the cost of the postage and envelopes; letters were
mailed in April of 2016 following IRB approval.
Maintenance of the intervention was evaluated at the initiation of the screening
implementation and throughout subsequent weeks. Long-term effects of the intervention
were evaluated and the researcher conveyed success of the specified intervention as
screening rates increased. Discussion with the providers ensued on an as-needed basis;
the researcher interviewed the providers after the screening was implemented to ensure
adherence and to answer any questions as they arose.
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Summary
With high prevalence of the Hepatitis C virus amongst the Baby Boomer
generation (those born between the years 1945 and 1965), it was evident that screening
for the infection or for the virus should be performed on this population. There are
various reasons as to why this population was deemed high-risk by the USPSTF (2015)
including blood or blood product transfusions prior to 1992 when universal screening was
implemented, receiving unregulated tattoos, or participating in intravenous drug use.
Regardless, a majority of the adults in this population might have an extended life span.
With current treatment available, it was prudent for them to be screened so treatment
might be initiated in a timely manner. Current treatment regimens yield an extremely
high success cure rate of 90-100% and therefore should be taken advantage of if a patient
is found to be HCV-positive. Overall, it is advantageous for this population to be
screened in order to obtain treatment as necessary and to ensure their life expectancy is
maximized.
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CHAPTER II

PROJECT DESCRIPTION

Literature Review Parameters
A review of the literature was performed on articles related to Hepatitis C virus
for the purpose of this capstone project. Identified databases and guideline literature
included the Centers for Disease Control and Prevention, the U.S. Preventive Services
Task Force, UpToDate, World Health Organization, Medline, ProQuest Nursing & Allied
Health Source, and PubMed. The review of literature spanned the years from 1999-2016.
Keywords included Hepatitis C virus, active Hepatitis C, chronic Hepatitis C, Hepatitis C
screening, Hepatitis C treatment, Hepatitis C genotypes, Liver cirrhosis, Perinatal
Hepatitis C, and Hepatitis C management. All of the researched articles and studies were
credible and from well-known, evidence-based databases, journals, and websites. Types
of studies included randomized controlled trials, systematic reviews, and quantitative
studies. All articles, studies, and guidelines were published in English.
Summary, Critical Review, and Synthesis of Literature
The USPSTF (2015) recommended that adults born between 1945 and 1965 be
screened once in their lifetime for the Hepatitis C virus. This guideline exists because
most of those patients with the Hepatitis C virus are in this specific general population.
Thus, it is prudent to screen this high-risk population since curative treatment is
available. The USPSTF was founded in 1984 and is comprised of a
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volunteer panel of national experts in prevention and evidence-based medicine.
The Task Force works to improve the health of all Americans by making
evidence-based recommendations about clinical preventive services such as
screenings, counseling services, and preventive medications. (USPSTF, 2016,
para. 1)
Such experts included those from various backgrounds including family medicine,
internal medicine, behavior health, obstetrics and gynecology, nursing, and pediatrics.
Their recommendations were devised after a thorough review of current peer-reviewed
evidence with intentions of assisting clinicians and patients to decide together whether a
preventive service was suitable for the needs of a patient (USPSTF, 2016, para. 2). The
USPSTF is closely affiliated with the Agency for Healthcare Research and Quality
(AHRQ) and has been since 1998. The AHRQ has been “authorized by the U.S.
Congress to convene the Task Force and to provide ongoing scientific, administrative,
and dissemination support to the Task Force” (USPSTF, 2016, para. 4). Annually, the
Task Force reports to Congress with regard to “critical evidence gaps in research related
to clinical preventive services and recommends priority areas that deserve further
examination” (USPSTF, 2016, para. 5).
The CDC (2015) is another credible resource that is renowned and evidencebased:
As the nation’s health protection agency, CDC saves lives and protects people
from health threats. To accomplish our mission, CDC conducts critical science
and provides health information that protects our nation against expensive and
dangerous health threats, and responds when these arise. (CDC, 2015, CDC’s
Mission section, para. 2)
This governmental resource offers clinicians up-to-date information regarding
recommendations, guidelines, useful information about the diseases such as transmission
patterns and risk factors, and incidence or prevalence of various diseases including the
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Hepatitis C virus. A “recent CDC analysis of death certificate found that HCVattributable deaths increased significantly between 1999-2007. CDC estimates that there
were 15,106 deaths caused by HCV in 2007” (CDC, 2016, How Many Deaths Can Be
Attributed to Chronic HCV Infection? section, para. 1). The CDC also reports various
testing methods and recommendations on vaccinations. Overall, this resource offers a
multitude of relevant and important information regarding a plethora of diseases from a
national and international standpoint.
Founded in 1948, the World Health Organization (WHO; 2016) is another vital
resource whose primary function is to direct and coordinate international health within
the system of the United Nations. Their focal areas of work include “health systems,
promoting health through the life-course, noncommunicable diseases, communicable
diseases, corporate services, and preparedness, surveillance and response” (WHO, 2016,
What We Do section, para. 1). The WHO understands that “early diagnosis can prevent
health problems that may result from infection and prevent transmission of the virus.
WHO recommends screening for people who may be at increased risk of infection”
(WHO, 2015, Getting Tested section, para. 1). Recognition of high-risk populations is
important to understand the magnitude of testing so individuals may be treated if
warranted. The WHO goes on to mention primary, secondary, and tertiary prevention.
While there is no current vaccination for the Hepatitis C virus, prevention is focused on
decreasing exposure to the blood-borne virus through good hand washing, proper
disposal of sharp objects including needles, proper education regarding condom use, and
thorough training of health professionals (WHO, 2015, Prevention section, para. 2).
Secondary and tertiary preventions include education and counseling with regard to
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treatment options and the importance of immunizations against Hepatitis A and B to
avoid coinfection of these viruses to protect the person’s liver. These types of prevention
also include prompt and appropriate medical management, including antiviral therapy if
warranted, and consistent monitoring for early identification of chronic liver disease
(WHO, 2015, Prevention section, para. 3).
UpToDate (2016) is another major resource that offers a wealth of information for
providers:
UpToDate is an evidence-based, physician-authored clinical decision support
resource which clinicians trust to make the right point-of-care decisions. More
than 6,300 world-renowned physician authors, editors, and peer reviewers use a
rigorous editorial process to synthesize the most recent medical information into
trusted, evidence-based recommendations that are proven to improve patient care
and quality. (para. 1)
The resource is unbiased as funding from pharmaceutical companies, commercial
entities, and medical device manufacturers is not accepted. The resource has been
utilized by more than 90% of U.S. academic medical centers and approximately 1.1
million providers in 180 countries and is affiliated with improved outcomes (UpToDate,
2016, para. 1). As aforementioned, this resource offers useful information regarding
HCV.
In their article, Chopra and Pockros (2015) provided current and relevant
information about various treatment options specific to the genotype and other patient
factors. Multiple “studies have suggested that these regimens, even at their introductory
high cost, are cost-effective for many populations, including those with genotype 1
infection or advanced fibrosis, because of their superior efficacy in clinical trials”
(Chopra & Pockros, 2015, Treatment Options section, para. 2). After 12 weeks of
treatment cessation, viral load should be checked to evaluate virologic response. While a
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“sustained virologic response (SVR) was traditionally defined as an undetectable viral
level at 24 weeks post-treatment, an undetectable level at 12 weeks post-treatment is
generally maintained through week 24” (Chopra & Pockros, 2015, Assessing a Treatment
Response section, para. 1). As aforementioned, management for the treatment-naïve
patient with HCV Genotype 1 should include interferon-free therapies with DAAs with or
without ribavirin depending on the specific combination. Chopra and Muir (2015) also
included management for treatment-experienced individuals. This type of patient has
failed prior treatment with peginterferon and ribavirin and are initiating antiviral
therapy now…The options are the same as for treatment-naïve patients and are
ledipasvir-sofosbuvir, ombitasvir-paritaprevir-ritonavir plus dasabuvir with or
without ribavirin, simeprevir plus sofosbuvir, and daclatasvir plus sofosbuvir.
(Chopra & Muir, 2015, Treatment-experienced Patients section, para. 1)
In his article, Pockros (2015) provided current, evidence-based information
regarding treatment of HCV. He found second generation DAAs (protease inhibitors)
were proven to be better tolerated by patients, they were affiliated with more transient
side effects, and they had been proven to be more effective with treating HCV genotype
1--the most common genotype in the United States. In their systematic review, Messina
et al. (2015) stated, “It is important to note that the most prevalent genotype in developed
economies (genotype 1) is also the most prevalent globally and should be well served by
interferon-free regimens of second-generation DAA therapies with viral eradication rates
of >90%” (p. 83). It is true that “treatment of chronic hepatitis C has evolved over the
last two decades, with 90%-100% of individuals now being cured” (Joshi, 2014, p. 664).
Hepatitis C viral infection is prominent globally and in the United States; it is
particularly prevalent amongst the Baby Boomer generation. The USPSTF (2015)
recommends this population (born between 1945 and 1965) be screened for HCV at least
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once in their lifetimes. The American Association for the Study of Liver
Diseases/Infectious Diseases Society of America (2015) supported this recommendation
with a rating of Class I, Level B (see Appendix E for classifications and descriptions). In
an article for The Journal for Nurse Practitioners, Hande (2014) also supported the
recommendation and stated,
A disproportionately high prevalence of HCV infection and HCV-related disease
is associated with these adults [“Baby Boomers”]. They are at greater risk for
hepatocellular carcinoma and HCV-related liver disease and comprise 73% of
HCV-associated mortality. (p. 64)
The author goes on to mention that a study conducted by “Liu et al. concluded that the
birth cohort screening provides nearly twice the benefit of risk-based screening alone” (p.
65).
Testing for the Hepatitis C virus includes anti-HCV antibodies and subsequent
HCV-RNA if the anti-HCV antibody test is positive or equivocal. The Ochsner Journal,
a peer-reviewed publication, has “several processes in place to ensure the Journal’s
compliance with the Committee on Publication Ethics (COPE) and the International
Committee of Medical Journal Editors ethics guidelines” (Amedee, 2015, p. 397). This
journal is known to be credible and reliable and is “committed to the highest levels of
professional standards and publication ethics and requires the same commitment from its
authors and peer reviewers” (Amedee, 2015, p. 397). Utilized for the purpose of this
capstone, this article relayed pertinent information regarding screening and testing for
HCV and its cost-effectiveness.
Joshi (2014) reported:
It is often difficult to know the exact cost of medical tests because of the lack of
transparency and negotiated pricing by insurance companies. Nevertheless, the
screening test for hepatitis C, anti-HCV antibody, offered by testing facilities or
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advertised on the internet costs $45-$80 for uninsured individuals and less when
covered by insurance. (p. 666)
Truly, this cost is nominal when one considers the big picture of the Hepatitis C virus and
its comorbidities including liver disease and hepatocellular carcinoma (HCC). With
proper counseling and education, a clinician can likely assist the patient in viewing the
big picture as opposed to looking at the issue from a perspective of less significance.
When one considers the cost of the disease burden of HCV itself, the cost of
testing pales in comparison. The quantitative study by Razavi et al. (2013), as
aforementioned, was found to be credible but did have some limitations:
The model does not explicitly account for alcohol consumption and metabolic
syndrome. Frequent heavy intake of alcohol significantly increases fibrosis
progression, and accelerated disease progression has been associated with
metabolic syndrome. (pp. 2168-2169)
Likely, the costs associated with HCV would be even higher if these aspects were
taken into account as alcohol is damaging to the liver and even more so when an
individual has underlying liver disease from HCV. Razavi et al. (2013) stated:
A limitation of prevalence measures used in this analysis is that high prevalence
populations may be undersampled through the NHANES. In particular,
undersampling of veterans, prisoners, and the homeless would result in
underestimation of the current prevalence, future disease, and cost burden. (p.
2169)
Ultimately, the costs are most likely higher than anticipated or estimated due to
the sequela of HCV. Healthcare costs are projected to rise as the incidence of advanced
liver disease increases. Razavi et al. (2013),
Lifetime healthcare costs for an HCV-infected person are significantly higher than
for noninfected persons, and the expected cost is higher among populations with a
higher life expectancy. Finally, it is possible to substantially reduce HCV
infection in the US through active management (p. 2169)
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Therefore, it is prudent to be screened and treated for HCV if tested positive to decrease
associated costs and increase years of life.
Several studies used the RE-AIM framework to evaluate screening procedures.
Glasgow, Vogt, and Boles (1999) indicated, “Public health interventions should be
evaluated more comprehensively than has traditionally been done. Dimensions such as
reach, adoption, and implementation are crucial in evaluating programs intended for
wide-scale dissemination” (p. 1325). Evaluation of a project or implementation change is
valid and necessary; often utilized is the RE-AIM framework (Virginia Tech, 2016). In
their systematic review, Gaglio, Shoup, and Glasgow (2013) identified 71 articles “after
excluding nonempirical articles, case studies, and commentaries” (p. e38), most of which
mentioned obesity, physical activity, and disease management. The RE-AIM framework
assisted in translating various types of research, including prevention and disease
management, into meaningful outcomes. Gaglio et al. stated:
RE-AIM was initially designed to help evaluate interventions and public health
programs, to produce a more balanced approach to internal and external validity,
and to address key issues important for dissemination and generalization. Over
time, it has expanded to include more diverse content areas, and is used in
planning in addition to reporting reviews. More recently, it has been applied to
policies and community-based multilevel interventions, as well as to reduce
health disparities. (e38)
Initially, the RE-AIM framework was utilized by a group of investigators predominantly
to assess research of health behaviors. Currently, it is used in the preparation stages to
assess development, report outcomes, and appraise the literature in various health areas
(Gaglio et al., 2013, p. e45).
A quantitative study by Liu and Perkins (2015) indicated screening rates were
increased after implementation of the lay cancer screening navigator. This is not unlike
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this researcher’s capstone project in utilizing providers in screening patients born
between 1945 and 1965 for HCV. The RE-AIM framework (Virginia Tech, 2016) was
utilized for their particular study and yielded success, particularly the efficacy
component. Of 1,394 qualified patients in this study, the lay cancer screening navigator
communicated with 91.9% of the patients. At “baseline, 28.6% of patients were current
on their colorectal screening, 40.5% at 6 months, and 42.2% at 12 months” (Liu &
Perkins, 2015, p. 280). It was clear to see that implementation of this resource, the lay
cancer screening navigator, increased screening rates in the population of adults between
50 and 74 years of age. Utilization of the RE-AIM framework assisted in appraisal of the
significance of interventions.
A systematic review conducted by Compernolle et al. (2014) identified 35
different intervention studies and applied the RE-AIM framework (Virginia Tech, 2016)
to them to ensure the authors of the studies met the components of this framework.
While not all of the intervention studies were found to meet all five components, it was
still deemed by the authors of this systematic review that the RE-AIM framework was
positively evaluated with regard to short-term behavioral changes but would likely need
more information regarding external cogency and “sustainability in order to take
informed decisions on the choice of interventions that should be implemented in realworld settings to accomplish long-term changes in obesity-related behaviours”
(Compernolle et al., 2014, p. 147). Although this systematic review did not identify
screening rates of a particular disease and lacked positive comparison to this researcher’s
current project and aim of identifying increased HCV screening, it was still beneficial to
observe how the RE-AIM framework was utilized amongst various studies.
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The literature was limited on EHR alerts and mailing informative letters for
Hepatitis C virus screening but there was pertinent literature with regard to other various
screening measures. The randomized controlled trial conducted by Sequist, Zaslavsky,
Marshall, Fletcher, and Ayanian (2009) provided validation for EHR alerts and mailed
reminders with subsequent increases in screening rates found in their study. This study
was conducted because screening for colon cancer, a leading cause of death, is a national
recommendation for adults 50 years and older; it is estimated that only about 60% of
eligible candidates are current on their screenings. Participants in this study “included
21,860 patients aged 50 to 80 years who were overdue for colorectal cancer screening
and 110 primary care physicians” (Sequist et al., 2009, p. 364). Creating an EHR alert
and mailing letters with regard to the importance of screening proved to increase rates of
screenings. Sequist et al. stated:
Screening rates were higher for patients who received mailings compared with
those who did not (44.0% vs 38.1%; P < .001). The effect increased with age:
+3.7% for ages 50 to 59 years; +7.3% for ages 60 to 69 years; and +10.1% for
ages 70 to 80 years (P=.01 for trend). Screening rates were similar among
patients of physicians receiving electronic reminders and the control group
(41.9% vs 40.2%; P=.47). However, electronic reminders tended to increase
screening rates among patients with 3 or more primary care visits (59.5% vs
52.7%; P=.07). Detection of adenomas tended to increase with patient mailings
(5.7% vs 5.2%; P=.10) and physician reminders (6.0% vs 4.9%; P=.09). (p. 364)
Overall, it was found that “mailed reminders to patients are an effective tool to promote
colorectal screening, and electronic reminders to physicians may increase screening
among adults who have more frequent primary care visits” (Sequist et al., 2009, p. 364).
In another randomized controlled trial, Ayanian, Sequist, Zaslavsky, and Johannes
(2008) aimed to discover if mailed reminders to physicians would increase their patients’
overdue colonoscopies. Not unlike an EHR alert for HCV, physicians were reminded of
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important screening opportunities for their patients. This study included 141 physicians
in Massachusetts in 2006 and 717 patients “who had colorectal adenomas removed
during 1995 through 2000 and no follow-up colonoscopy identified via automated review
of electronic records through March, 2006” (Ayanian et al., 2008, p. 762). Ayanian et al.
stated:
The use of colonoscopy and detection of new adenomas or cancer were assessed
at 6 months by a blinded medical record review in all patients. Among 358
patients whose physicians received reminders, 33 (9.2%) patients underwent
colonoscopy within 6 months, compared with 16 (4.5%) of 359 patients whose
physicians did not receive reminders (P=0.009). In prespecified subgroups, this
effect did not differ statistically between 2 primary care networks, elderly and
nonelderly patients, or women and men (all P>0.60 by Breslow–Day test). New
adenomas or cancer were detected in 14 (3.9%) intervention patients and 6 (1.7%)
control patients (P=0.06), representing 42.4% and 37.5% of patients who
underwent colonoscopy in each group, respectively. Despite using advanced
electronic health records to identify eligible patients, 22.5% of enrolled patients
had a prior follow-up colonoscopy ascertained only by visual record review, and
physicians reported 27.9% of intervention patients were no longer active in their
practice. (p. 762)
Ultimately, for patients who were diagnosed with colorectal adenomas, mailing
reminders to their physicians proved to increase colonoscopy screenings.
Summary
This extensive literature review provided evidence-based, relevant, and current
information regarding the Hepatitis C virus. It is clear that HCV is a current problem
both globally and nationally and a virus affiliated with six different genotypes. The HCV
genotype 1 is the most prevalent in the United States and has been found to respond well
to treatment with second generation DAAs. These pharmaceutical interventions
generally yield more transient and therefore more tolerable side effects with a 90%-100%
cure rate. Screening the identified birth cohort would be advantageous since prevalence
of HCV amongst this population currently far exceeds any other birth cohort. While the
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literature was limited with regard to specific increases in HCV screening rates via letters
or alerts in the EHR, literature did exist for other various screenings including colorectal
cancer screening, which yielded higher rates of screening when letters were mailed to
patients or when a patient attended three or more visits with their primary care providers.
Project Objectives
The main objective of this project was to increase providers’ awareness of the
USPSTF’s (2015) recommendation to screen for HCV with the focus on subsequent and
projected increased screening rates measured through the EHR of the identified birth
cohort (adults born between 1945 and 1965). Increasing providers’ awareness of this
recommendation is important so they understand the magnitude of HCV screening for the
identified birth cohort as 75% of adults with HCV were born during this time frame.
Eagle Ridge Medical and the Fort Lupton clinic currently do not have a standardized
approach to screen for HCV. After a meeting with the providers of the clinic, it was
brought to this researcher’s attention that only select patients had been screened and
generally only if they had physiological symptoms that warranted the screening measure.
High-risk behavioral history questions of the patients such as intravenous drug or if the
patient had received a blood or blood product transfusion before the year of 1992 were
also not asked on a regular basis. It is important to understand the reasoning behind
screening this birth cohort as adults in this particular birth cohort are “5 times more likely
than other adults to be infected. In fact, 75% of adults with Hepatitis C were born in
these years” (CDC, 2012, This Hepatitis C Testing Recommendation Was Made Because
section, para. 1).
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The objective was carried out by creating an alert reminder in the EHR for
providers to screen for HCV if the patient was born in the years 1945 to 1965.
Informative letters notifying the patient of the USPSTF’s (2015) recommendation to be
screened for a blood-borne disease were also mailed to the Baby Boomer generation in
case they had not made an appointment at the clinic over the next several weeks and
would not have been given the opportunity to be screened for HCV otherwise. With the
high accuracy of testing results and current treatment available, screening this high-risk
population is important and warranted. Identifying seropositive individuals not only
gives the potential to treat and prolong a certain individual’s life but also provides an
opportunity for education regarding transmission and how to decrease the likelihood of
spreading the virus to a loved one, friend, or stranger.
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CHAPTER III

PROJECT DESIGN

Evidence-Based Project Plan
This capstone project was implemented due to the fact that the Eagle Ridge
Medical and Fort Lupton clinics did not currently have a standardized implementation
process of screening all adults born between 1945 and 1965 for HCV as recommended by
national screening guidelines; 100% of the physicians at this clinic (N = 4) agreed to take
part in this project by screening the specified patient population for HCV. The purpose
of this project was to increase screening rates of HCV in this birth cohort by
implementing an alert in the EHR (a screening reminder to act as a cue to action for the
providers) for this birth cohort, which prompted providers to screen and counsel these
patients on HCV. Informative postal letters indicating the patient was recommended by a
group of national experts to be screened for a blood-borne disease were also mailed to
this birth cohort if an appointment was not achieved during the initial project
implementation to ensure this entire population of Eagle Ridge Medical and the sister
clinic in Fort Lupton was being reached. The providers at Eagle Ridge (who are also
affiliated with the Fort Lupton clinic as two are the same providers at both clinics)
requested the letter be generic and it included the national recommendation from the
USPSTF (2015) to be screened for a blood-borne disease (see Appendix F for the letter).
Discussion with the office manager and providers occurred prior to implementation in the
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EHR to clarify the practice change and discuss its significance. This researcher provided
the background of the literature review to exemplify the evidence-based research
supporting this practice change. A fact sheet (see Appendix G) from the CDC (2012)
was also made available to patients who were counseled or screened for HCV. This fact
sheet was available to patients in the lab of the clinic where they underwent a peripheral
blood draw for testing.
The USPSTF is a government entity that guides medical practices and providers.
Eagle Ridge Medical and the sister clinic in Fort Lupton are not exempt from this and are
clinics with a goal to adopt standards of practice to ensure the best possible care is being
delivered to their patients. Since Hepatitis C virus screening is a Grade B
recommendation (USPSTF, 2013) and something not currently being done at Eagle Ridge
Medical and the Fort Lupton clinics, the office manager approved this practice change
and believed it to be pertinent. Other renowned resources include the CDC (2016) and
the WHO (2015), which also support the screening recommendation from the USPSTF
(2015). The Baby Boomer generation has been proven to be a high-risk population and a
one-time screening is recommended. Current pharmacological treatment regimens exist
and yield high success rates of viral eradication. Therefore, it behooves Eagle Ridge
Medical and the Fort Lupton clinic to offer HCV screening to this birth cohort that utilizes
their clinic for medical care and refers for treatment if warranted.
Timeline
The timeline for this capstone project was as follows:


Meeting with office manager and four providers at Eagle Ridge Medical and
the Fort Lupton clinics to increase awareness of USPSTF’s (2015)
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recommendation and EHR implementation of screening reminder for HCV-February 2016


Proposal defense/IRB approval of capstone--March 2016/April 2016



Mail informative letters to patients (following IRB approval)--April 2016



CDC (2012) fact sheet handouts available in the lab of the clinic--April
2016



Chart audit prior to implementation of screening reminder in EHR and
mailing of informative letters to obtain baseline screening rate--April 2016



Chart audit after implementation of screening reminder in EHR and
informative letters mailed to obtain subsequent screening rate--May 2016



Program development--March to June 2016



Capstone defense--June 2016
Resources, Personnel, Technology, and Budget

Personnel resources include one office manager, four physicians, and five medical
assistants (MAs). The office manager is in charge of ensuring successful implementation
of the screening reminder into the EHR (see Appendix H for an example of a typical
screening reminder) and also ensures implementation of the flow sheet. Note that the
screening reminder example in Appendix H is of a test patient and does not identify an
actual patient. The screening reminder for HCV screening for the providers says
“Hepatitis C Screening.” The flow sheet is a table within the EHR that informs the
provider if the patient has or has not been screened or if the patient refuses screening.
The physicians execute counseling and screening methods of the identified birth cohort
and acknowledge the screening reminder in the EHR. The medical assistants support the
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practice change by executing the standing order for the anti-HCV antibody test
implemented for patients who requested testing based on the recommendations in the
informative letter. In this case, the patient does not need to schedule an appointment with
their provider (unless they desire to do so) and could simply come to the clinic for the
blood draw. All four physicians (100%) agreed upon implementation of a standing order
for the MAs to draw the anti-HCV antibody in the lab. The CDC fact sheet was also
disseminated to patients in the lab per request of the office manager and physicians.
Normal results will be mailed to the patients. Patients who test positive for HCV will be
called and instructed to make an appointment with their provider. Positive results will
not be relayed over the phone as the patient will be instructed to come to the clinic for an
appointment. The administrative staff of the clinic will ensure each new patient
completes the Acknowledgement of Notice of Privacy Practices and HIPAA Consent
upon their initial appointment that is updated annually at the clinic by the patient (see
Appendix I for a copy of the form). While there is a section on the form that identifies
the patient’s consent to discuss care/test results, sensitive information such as results
from HCV testing are not disclosed.
Other sensitive information not disclosed included but was not limited to human
immunodeficiency virus (HIV) results, sexually transmitted disease (STD) results, or
pregnancy test results. A section on this form also gives the patient a “yes” or “no”
option with regard to whether confidential information can be left on voice mails or
answering machines. However, sensitive information or results such as the ones
aforementioned are not left on a voice mail or answering machine regardless of the
patient’s consent on this form. To ensure the staff is speaking to the correct patient
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before relaying information in general, the patient is asked his/her full name and date of
birth and the staff verifies the information on the patient’s chart in the EHR before any
results are given. The author of this project protected identity of patients by not
disclosing any protected health information (PHI) including name, date of birth,
diagnosis, social security number, address, or any other sensitive information she had
access to from the EHR. The utilized data for collection purposes were strictly limited to
a percentage of the population screened prior to and after implementation of the EHR
alert (screening reminder) and did not contain any PHI of any nature.
Additional equipment other than what was already stocked at Eagle Ridge
Medical and the Fort Lupton clinics was not necessary. The labs at the clinics were
already stocked with the appropriate materials needed for HCV testing including
tourniquets, serum tubes, venipuncture needles, vacutainers, gauze, and tape. The clinic
utilizes the EHR system; costs for creating an alert for the HCV screening reminder and
the flow sheet were assumed by the clinic.
Items necessary for collecting of blood for the HCV tests were already available
in the setting and further costs were not projected to increase as the clinics had a plethora
of these specific supplies. The only projected cost of this project was the informative
postal letters mailed to patients born between the years 1945 and 1965. The current cost
of a stamp was $0.49 and the office manager agreed to purchase these stamps with the
budget from the clinic. While exact costs for these items were unavailable due to the fact
that items were mailed from the main affiliated hospital, Platte Valley Medical Center,
costs were estimated to be less than $2,000 and were assumed by Eagle Ridge Medical
and its sister clinic in Fort Lupton. Costs were also taken into account regarding letters
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that would be mailed notifying patients of all normal HCV results. Currently, 1,906
persons born between 1945 and 1965 are patients of Eagle Ridge Medical at the Brighton
and Fort Lupton locations. The Fort Lupton location is being used as well because two of
the physicians at Eagle Ridge Medical in Brighton float to this clinic during the week and
therefore many patients utilize both clinics. Again, while it is difficult to produce an
exact cost of the anti-HCV antibody test for an insured patient, an uninsured patient
would assume $47.00. This researcher obtained the cost of the test from the billing
department at Eagle Ridge Medical and the Fort Lupton clinics.
Additionally, no risks or threats were affiliated with this capstone project.
Benefits of implementation of this project included increased provider awareness of the
USPSTF (2015) recommendation to screen the Baby Boomer population for HCV and
the significance of the screening as current treatment is available that yields a high
success cure rate.
Evaluation Plan
Evaluation of the plan, which included two phases (pre- and post-intervention of
the project), was assessed by first performing a chart audit of 5% of the 1,906 established
patients at Eagle Ridge Medical and the Fort Lupton clinics (n = 95) and a chart audit of
patients seen at the clinics six weeks prior to the implementation date who were born
between 1945 and 1965 to establish a baseline screening rate for HCV among eligible
patients. This occurred prior to implementation of the alert reminder in the EHR and
mailing of informative letters to patients. This number was compared to a chart audit of
95 patients, representing 5% of the 1,906 established patients; these patients were seen at
the clinics six weeks after the implementation date screened for HCV, after
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implementation of the alert reminder in the EHR, and after mailing informative letters to
this birth cohort. This researcher tracked absolute screening results of both the alert
reminder in the EHR and mailing of letters and therefore did not discriminate between the
two methods in the results section. It was this researcher’s assumption that screening
rates of patients for HCV would increase in this birth cohort after implementation of the
alert reminder in the EHR was created and informative letters were mailed. When a
patient was screened for HCV, the provider or administrative staff updated information
within the EHR system to prevent duplicative screening of patients if they came to the
clinic for subsequent visits after having been screened once before.
This researcher protected each patient’s identity during the chart audits (prior to
and after this project implementation) by ensuring the audits were done at the clinic
utilizing only a clinic-approved computer and ensuring the audits were being performed
in an area from which patients were restricted. The audits took place within one of the
physician’s offices; sensitive information such as a patient’s name, birth date, home
address, or phone number was not generated in the results or findings of this capstone.
This researcher did not discuss any sensitive patient information with any employee or
provider of the clinic who was not on a “need-to-know” basis and did not discuss any
information with any individual outside of the clinic setting. The researcher adhered to
the strict policies of HIPAA and fully understood the ramifications.
Summary
All four physicians involved in this study understood that the USPSTF’s (2015)
recommendation of screening adults born between 1945 and 1965 for HCV was useful
and important. By educating the providers, this researcher successfully increased the
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providers’ awareness of HCV and therefore the importance of screening this birth cohort.
Eagle Ridge Medical and the Fort Lupton clinics did not currently have a screening alert
(reminder) established within the EHR. The four physicians admitted they had not
screened this birth cohort before based on the USPSTF’s recommendation and without
alarming medical symptoms that might have prompted them to screen these adults in the
past. The recommendation to screen this birth cohort was without regard to medical
symptoms and therefore asymptomatic adults were recommended to be screened.
Ultimately, this researcher anticipated that screening rates would increase once the
screening alert (reminder) was implemented within the EHR and as a result of mailing
informative letters to patients born between 1945 and 1965. The letter was generic based
on the physicians’ requests, included the USPSTF’s recommendation for screening of a
blood-borne disease, and informed the patient to ask about the screening at his/her next
appointment. Costs affiliated with this project were projected to be less than $2,000 and
were mainly associated with envelopes and postage to mail the informative letters and
normal results. The clinic utilized the EHR so further costs from support and changes
within this system for the development of the screening reminder (alert) and flow sheet
were not incurred. Overall, this researcher anticipated an increase in screening rates
amongst this birth cohort after implementation of the screening alert (reminder) in the
EHR was executed. It was also anticipated that the screening rates would increase once
patients received the informative letters from the clinic and came in to have their blood
drawn to test for HCV.
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CHAPTER IV

RESULTS AND OUTCOMES

The objective of this capstone project was to increase screening rates of patients
born in the “Baby Boomer” generation (born between the years of 1945 and 1965) at the
Eagle Ridge Medical (in Brighton) and the Fort Lupton clinic. This chapter presents the
results based on the planned evaluation. Two different methods were utilized for
establishing baseline screening rates; they included a chart audit of 5% of the whole
population of adults born between 1945 and 1965 at both clinic sites and a chart audit on
all patients born in this timeframe who were seen at both of these clinic sites in the six
weeks prior to informative letters being mailed and the alert reminder for HCV screening
in the EHR. These two different methods were utilized to gather screening rates on
active patients (patients seen in the last six weeks) and a random chart audit of all
registered patients to reach less actively seen patients.
Results Linked to Problem Statement
and Evaluation Plan
A chart audit was performed on 5% (n = 95) of the 1,906 patients of Eagle Ridge
Medical and the affiliated Fort Lupton clinic as two of the physicians at Eagle Ridge
Medical floated to this sister clinic a couple of days per week. The list of patients was
compiled from MDS and initially, 1,933 patients were listed. Subsequently, 27 patients
were excluded for various reasons: 18 were duplicate patient entries into the EHR, four
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were deceased, three were discharged from the practice, and two were test patients. Data
for the chart audit were collected by auditing every 10th patient in alphabetical order. Of
the 95 patients audited for the purpose of this chart audit, three patients had been
screened already, which resulted in 3.2% of this population. Three different physicians
ordered the anti-HCV antibody tests on their patients; one of the physicians worked at
Eagle Ridge Medical while the other two physicians worked at an affiliated internal
medicine office in Brighton and another family practice clinic located at the Reunion site
in Commerce City. All three of these patients were screened in the last two years. One
of the physicians ordered the test because of an increased liver function test (LFT)--ALT
of 77 (normal range: 21-72) and aspartate aminotransferase (AST) of 66 (normal range:
17-59). Another patient was tested due to a slight increase in LFTs (ALT of 59 and AST
of 45) per the physician. The third patient was tested due to unknown reasons. The
physician did not justify or state the reason in the affiliated progress note. All three of the
patients tested from this chart audit were negative for the Hepatitis C virus.
Four hundred sixty-seven patients were seen in the six weeks before project
implementation and born within the time frame of 1945 to 1965. One patient was
excluded from the review due to death within the time period, which left 466 patients for
the purpose of this chart audit to establish baseline screening rates. Three of the 466
patients seen in the past six weeks were screened for HCV, which meant 0.6% of this
population was screened for the Hepatitis C virus prior to implementation of the
screening alert in the EHR and mailing of informative letters. One patient requested the
HCV testing as well as screening for HIV and STDs. The reasoning behind this request
was not documented in the record. The second patient requested testing for HCV
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because, per the physician’s progress note, he admitted to having unprotected sexual
encounters with multiple partners and was experiencing fatigue. The third patient was
tested for HCV due to a rash and his significant other requesting he be tested for STDs
that included blood-borne diseases. All three patients tested for HCV in the past six
weeks had negative results and all three physicians who ordered the anti-HCV antibody
tests worked at Eagle Ridge Medical.
An alert reminder was created in the EHR for the providers to screen for HCV if a
patient was born in the years 1945 to 1965. Informative letters intended to notify the
patient of the USPSTF’s (2015) recommendation to be screened for a blood-borne
disease were also mailed to the Baby Boomer generation in case they did not achieve an
appointment at the clinic over the next several weeks and therefore would not have been
given the opportunity to be screened for HCV otherwise.
The researcher met individually with all four physicians seven calendar days after
initiation of this project (implementation of the alert within the EHR and mailing of
informative letters). The researcher met with the physicians to ensure they were
acknowledging the alert in the EHR and subsequently screening the Baby Boomer
population. All four physicians (100%) stated they had been screening this population
and the alert in the EHR was helpful as a reminder. All of the physicians agreed and
admitted that by the end of the appointment with the patient, sometimes they would
forget to screen the patient as the alert popped up immediately when the patient’s chart
was opened and disappeared after one acknowledged it. Regardless, all four physicians
felt the screening rate for each of them had definitely increased. They denied having any
questions or concerns at that time.
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A chart audit was performed on 5% of the 1,906 patients (n = 95) of the Eagle
Ridge Medical and Fort Lupton clinic at the end of the six-week mark. Results of the
chart audit were collected by auditing every 10th patient in alphabetical order following
the first 95 patients who were previously audited. Of the 95 patients audited, seven of
them had been screened (7.3%), an increase of 4.1% in comparison to the similar chart
audit completed (which was 3.2%) prior to initiation of the interventions. Of the seven
patients screened, three were screened in the past six weeks due to the recommendation
as they were born between the years 1945 and 1965 and the remaining four were
screened for various reasons. One patient was screened because this individual worked
with HIV-positive children and requested HIV testing as well as HCV testing. Another
patient, a widow, was screened per request for STD testing including blood-borne
diseases in case this person pursued another relationship. Per the physician’s progress
note, this patient denied symptoms or concerns regarding exposure. The other patient
was tested due to a slightly increased AST (49) with a normal range of 14-36. The ALT
was within normal limits (39) and this patient, per this physician’s progress note, denied
use of alcohol. All seven patients screened from this chart audit tested negative for the
Hepatitis C virus. All three physicians who ordered these tests worked at Eagle Ridge
Medical in Brighton and these patients were all screened within the last three years.
A chart audit was performed six weeks after implementation of the screening
reminder alert in the EHR and mailing of informative letters. The chart audit was
performed on 421 patients seen in the previous six weeks. Of the 421 patients seen, 57
(13.5%) were screened for HCV due to the recommendation. There was a 12.9%
increase from the initial baseline screening rate of 0.6%. Of the 57 patients screened
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after implementation of the alert in the EHR and mailing of informative letters, 56
patients tested negative for the Hepatitis C virus and one patient tested positive (reactive
to hepatitis C) with the subsequent genotype 1a and an RNA of 14,200,000 IU/mL, which
meant the patient had active, chronic Hepatitis C. Per the physician, the testing was done
due to the recommendation but the patient did admit to having chronic fatigue as well.
The researcher of this project investigated the patient’s comprehensive metabolic panel
and the patient had an ALT of 43, AST of 25, and a total bilirubin level of 0.4. All of
these test results were within the normal range. Table 1 provides the screening rates prior
to and after project implementation

Table 1
Screening Rates Prior to and After Project Implementation
Pre-Project
Implementation

Post-Project
Implementation

Patients born between 1945-1965

1906

1906

Population screened using 5%
(n = 95) systematic sampling

3 (3.2%)

7 (7.3%)

Patients seen in clinic in 6-week study
period

466

421

Patients seen

3 (0.6%)

57 (13.5%)

Total Clinic Population Screening Rate

Clinic Patients Seen by Provider Screening
Rate

44
Extent to Which Objectives Were Achieved
It is clear to see the objectives of this capstone project were achieved. The
physicians agreed they were all screening the patient population based on the USPSTF
(2015) guidelines and screening rates increased. The researcher of this capstone project
expected rates to increase more than 13.5%; however, perhaps with a longer timeframe,
rates would have increased even more. The alert reminder in the EHR was effective in
increasing the screening rate, although it had limited reach in the clinic’s population.
This researcher assumes the screening will continue to increase, even though the alert in
the EHR for HCV screening has been deleted, because of the informative letters mailed
to this patient population as this was the best method of reaching the majority of the
patients. The researcher anticipates some of the patients who received the letters might
not have come to the clinic yet or were waiting until a future appointment (e.g., a
physical) until they asked what the screening entailed.
Key Facilitators and Barriers
Key facilitators primarily included the physicians of Eagle Ridge Medical and the
Fort Lupton clinic who agreed to screen this patient population based on USPSTF’s
(2015) recommendations. All four physicians (100%) stated compliance with screening
the patients born between 1945 and 1965 and found it was helpful to have a reminder
(screening alert in the EHR) to prompt them. The researcher identified an increase in
screening rates both due to the physicians screening the patients during their
appointments and due to the informative letters mailed to the patients. The researcher
combined results of patients being screened in the clinic and letters mailed in collecting
this data; therefore, she was unable to determine which patients were screened for HCV
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due to the providers doing so from the alert reminder in the EHR or from the informative
letters the patients received in the mail.
The front desk staff and the Medical Assistants were also key facilitators as they
received multiple phone calls with regard to the letters and answered them appropriately
by telling the patients they did not need to accomplish an appointment with their provider
if they simply wanted to come to the clinic for the blood draw. The Medical Assistants
informed this researcher that they drew multiple patients’ blood for HCV. They mailed
normal results to the patients who had normal (negative) findings but for the patient who
was found to be positive for HCV, they called the patient to inform this person to make
an appointment with their physician. The Medical Assistants did not relay the positive
result over the phone as this was the physician’s responsibility. The Medical Assistants
also offered the Fact Sheet from the CDC (2016; see Appendix G) that was made
available in the lab of the clinic for patients.
The researcher was a key facilitator as she made multiple contacts with MDS in
ensuring the EHR trigger alert (reminder) was implemented appropriately and was
activated for all patients born between 1945 and 1965 at the Eagle Ridge Medical and
Fort Lupton locations. She spent 45+ hours hand-addressing all 1,906 envelopes, printing
the letters, stuffing the envelopes with the letters to patients born between these years,
and ensuring the letters were mailed to patients. The researcher was readily available for
any questions or concerns the office staff had. No significant barriers were identified
with this capstone project although it would have been more cost and time efficient if the
EHR could have generated letters and mailing labels for not only this informative letter
but any future informative letters.
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Recommendations
Overall, the researcher deemed this capstone project as beneficial and successful
in increasing the screening rates for HCV of the Baby Boomer population. The
physicians and office manager all agreed this project was useful and worthwhile and the
physicians made great efforts in screening the patients during appointments. They
relayed the importance of the EHR screening reminder alert and said it did indeed prompt
them to screen patients. The Medical Assistants were an essential part of this project as
they received “walk-in” patients who received letters in the mail and the front desk staff
answered multiple phone calls with regard to the letters and gave patients appropriate
information.
There were no unintended consequences of this capstone project but the
researcher, as she anticipated, identified a significantly higher increase of screening rates
for the Hepatitis C virus amongst the Baby Boomer generation in the six-week period.
The researcher assumed the screening rate would increase more after implementation of
the screening alert (reminder) in the EHR and mailing of informative letters and
anticipates the screening rate will continue to rise over time. The researcher noted a
4.1% increase of screening rates when she did the chart audit on 5% of the 1,906 patients
(n = 95) at the Eagle Ridge Medical and Fort Lupton sites and a 12.9% increase when she
did the audits of patients seen in the six weeks prior to and six weeks after project
implementation (alert reminder in the EHR and mailing of informative letters). While the
physicians stated they were screening this patient population, they all admitted they
sometimes forgot to screen a patient for HCV as the alert reminder in the EHR only
appeared upon opening the patient’s chart. It is understandable how a provider might
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forget to screen the patient or order the test at the end of the appointment. The physicians
informed this researcher that many patients who were offered the screening had declined
it for various reasons (such as they were already screened once before or they did not feel
they were considered high-risk). However, this author was not able to capture an exact
number of patients who refused screening because the physicians did not consistently
annotate this in their progress notes. Per the physicians’ progress notes, the researcher of
this capstone noted eight documented patients who declined the screening. The reasons
varied including three patients felt they were not high-risk, four patients stated they had
been screened before, and one patient stated they did not have time for a blood draw that
day but might return to the clinic at a later time.
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CHAPTER V

RECOMMENDATIONS AND IMPLICATIONS FOR PRACTICE

The objectives of this Capstone project were to increase screening rates of
patients born between 1945 and 1965 at the Eagle Ridge Medical and Fort Lupton clinic
sites. These objectives were carried out by implementing an alert reminder in the EHR to
act as a cue for providers to screen this high-risk population and also by mailing
informative letters to the entire patient population at both of these sites (N = 1,906) to
ensure all patients born in this timeframe were being reached. In this chapter, the
researcher provides recommendations for the clinics where this project was implemented
and how the project would likely prove to be beneficial in further increasing screening
rates if continued. The researcher also includes recommendations regarding
implementation of this project in other family practice settings as it is applicable and
beneficial.
Recommendations
It is this researcher’s recommendation that the project conducted on screening the
Baby Boomer generation (adults born between the years 1945 and 1965) for the Hepatitis
C virus at Eagle Ridge Medical and the Fort Lupton clinics be continued. The alert
reminder in the EHR was turned off after the six-week mark; however, it would likely be
beneficial to keep this alert in place to prompt and remind the providers to screen this
patient population for HCV. This would be especially useful for new patients of the
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clinic and for patients the letters did not reach. Out of the 1,906 letters mailed, 90 of
them were returned (4.7%) primarily due to the patient no longer living at a specified
address. Other recommendations this researcher makes include:


The informative letter be included with each “new patient” packet made
available at the clinic for patients born between the years 1945 and 1965.
This way the entire Baby Boomer population at these family practice clinics
will be reached including new patients as letters were already sent to
established patients born in this timeframe.



The alert reminder be generated for the Medical Assistant so the alert can be
addressed and consent obtained for ordering the test to save the provider
time. The provider would then see the test had been ordered and not
duplicate it.



Implement a change within the EHR so the alert reminder is generated under
the “Plan” page. This is where the providers order tests and prescribe
medications and would be a beneficial area within the EHR to have this alert
because the provider could mention it to the patient and order it if the patient
was willing to undergo the testing.

It is understandable that these types of newer national recommendations take time
to integrate into practice. It is the researcher’s hope that if this screening
recommendation for HCV is continued in the EHR, the providers and Medical Assistants
will become accustomed to screening the Baby Boomer population without having the
alert reminder prompt them. Implementing the alert in the “Plan” of the EHR is a type of
automatic screening similar to colonoscopies or mammograms; these screenings seem
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engrained in most providers and are generally offered without needing the EHR alert
reminder. There are no ongoing evaluations needed for phases outside the scope of this
DNP project at this time.
Within the framework of the organization’s strategic plan, the providers and the
office manager would need to be in agreement that this recommendation of screening
adults born between 1945 and 1965 is useful and beneficial, especially from a long-term
aspect. The office manager and providers are aware treatment is available for individuals
who have active, chronic HCV and understand referrals to gastroenterologists or
hepatologists are deemed warranted and necessary for a patient to begin a treatment
regimen. If screening the Baby Boomer population for HCV was to continue, the office
manager would need to disseminate the message to the Medical Assistants and the front
desk staff to ensure everyone is aware of the screening and to require the informative
letters be a part of a “new patient” packet. The Medical Assistants would likely be
responsible for ensuring the lab area was always stocked with the Fact Sheet from the
CDC (2016) and the lead Medical Assistant would perhaps be responsible for ensuring
this Fact Sheet was updated by looking at the CDC website at least quarterly.
This capstone project would definitely be applicable in other family practice
settings. It is a national recommendation from the USPSTF (2015) to screen all Baby
Boomer generation patients at least once in their lifetime. As seen from the researcher’s
chart audits at Eagle Ridge Medical and Fort Lupton clinics, a small amount of patients
had been screened prior to implementation of this project. The researcher anticipates
most clinics in the nation do not have a standardized approach for screening this
population for HCV, especially if the patient is asymptomatic. It is important to
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understand that this population is deemed high-risk and therefore screening is warranted
and recommended. Education would likely need to be delivered regarding not only the
importance of the screening but also with regard to treatment availability and the high
success cure rate (90-100%).
Contribution to Personal Goals
This researcher felt this capstone project contributed to her personal goals as an
advanced practice nurse and as a leader. She felt she was organized and focused; she
effectively disseminated the message regarding Hepatitis C screening in the Baby
Boomer population by creating the alert within the EHR system and mailing letters to the
entire patient population at the Eagle Ridge Medical and Fort Lupton clinic sites. Often
times, education is spread by “word of mouth” and it was this researcher’s thought that
patients who heard about HCV screening (either through an appointment with their
provider or receiving an informative letter in the mail) would then discuss it with other
people including family members or friends and, subsequently, the recommendation of
this screening would be dispersed. After conducting this type of capstone project, this
researcher is excited about the potential of implementing similar types of evidence-based
changes amongst practices in the future. Eagle Ridge Medical is an innovative clinic that
certainly seems to embody the importance of maintaining the most current
recommendations and evidence in order to provide the best possible care to the patients
they serve. It is this researcher’s hope that most family practice clinics are similar to
Eagle Ridge Medical in this regard.
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Summary
Screening this high-risk population, adults born between the years 1945 and 1965,
for the Hepatitis C virus is a Grade B recommendation from the USPSTF (2015) and one
worth doing. The researcher of this capstone project deemed it successful as screening
rates increased after implementation of the alert reminder in the EHR, prompting the
physicians to screen this high-risk population, and mailing of informative letters to
capture the entire patient population at the Eagle Ridge Medical and Fort Lupton clinic
sites. It is likely other family practice clinics would benefit from screening the Baby
Boomer generation as well as it would allow the opportunity for treatment if patients
tested positive for HCV. The researcher of this capstone project felt this project was
successful even though a drastic increase of screening rates was not seen. An increase
was seen overall and was particularly notable with the short, six-week timeframe.
Perhaps a longer timeframe would have proven to be more successful in increasing
screening rates. With that being said, however, the researcher thoroughly enjoyed
working on this project and felt it enhanced her personal leadership goals by effectively
implementing a beneficial change amongst a family practice setting.
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Level of Certainty

Source. U.S. Preventive Services Task Force (2013).
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APPENDIX C
TOTAL PREVALENCE AND HEALTHCARE COSTS
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Total Prevalence and Healthcare Costs with 95% CIs

Source. Razavi et al. (2013).
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APPENDIX E
RECOMMENDATIONS FOR TESTING, MANAGING,
AND TREATING HEPATITIS C
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Source. American Association for the Study of Liver Diseases/Infectious Diseases
Society of America (2015).
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APPENDIX F
LETTER TO PATIENTS
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Eagle Ridge Medical Clinic
1606 Prairie Center Pkwy #240
Brighton, CO 80601
303-659-1152

To whom it may concern,
You are receiving this letter because you are born between the years 1945-1965. The
United States Preventive Services Task Force (USPSTF), a group of national experts in
evidence-based medicine that focus on keeping people well, recommends screening
adults born between these years for a blood-borne disease.
Please ask about the details of this screening at your next appointment with your provider
or contact the clinic at 303-659-1152 if you wish to learn more. The testing includes
checking your blood.
Sincerely,
Eagle Ridge Medical Staff
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